Inhibition of allogeneic cytotoxic T cell (CD8+) proliferation via polymer-induced Treg (CD4+) cells
Source abstract
Abstract
T cell-mediated immune rejection remains a barrier to successful transplantation. Polymer-based bioengineering of cells may provide an effective means of preventing allorecognition and the proliferation of cytotoxic (CD8+) T lymphocytes (CTL). Using MHC-disparate murine splenocytes modified with succinimidyl valerate activated methoxypoly(ethylene glycol) [SVA-mPEG] polymers, the effects of leukocyte immunocamouflage on CD8+ and CD4+ alloproliferation and T regulatory (Treg) cell induction were assessed in a mixed lymphocyte reaction (MLR) model. Polymer-grafting effectively camouflaged multiple leukocyte markers (MHC class I and II, TCR and CD3) essential for effective allorecognition. Consequent to the polymer-induced immunocamouflage of the cell membrane, both CD8+ and CD4+ T cell alloproliferation were significantly inhibited in a polymer dose-dependent manner. The loss of alloproliferation correlated with the induction of Treg cells (CD4+CD25+Foxp3+). The Tregs, surprisingly, arose primarily via differentiation of naive, non-proliferating, CD4+ cells. Of biologic importance, the polymer-induced Treg were functional and exhibited potent immunosuppressive activity on allogeneic CTL proliferation. These results suggest that immunocamouflage-mediated attenuation of alloantigen-TCR recognition can prevent the tissue destructive allogeneic CD8+ T cell response, both directly and indirectly, through the generation/differentiation of functional Tregs. Immunocamouflage induced tolerance could be clinically valuable in attenuating T cell-mediated transplant rejection and in the treatment of autoimmune diseases. While our previous studies have demonstrated that polymer-grafting to MHC disparate leukocytes inhibits CD4+ cell proliferation, the effects of PEGylation on the alloproliferation of CD8+ cytotoxic T cells (CTL) was not examined. As shown here, PEGylation of allogeneic leukocytes prevents the generation of the CTL response responsible for acute rejection. The loss of CTL proliferation is consequent to the polymer-based attenuation of allorecognition and the induction of T regulatory cells (Tregs). Interestingly, the Tregs are primarily generated via the differentiation of non-proliferating naive T cells. Importantly, the Tregs are functional and effectively induce a tolerogenic environment when transferred to an alloresponsive environment. The use of polymer-modified leukocytes provides a unique approach to effectively maximize the biologic production of functional Tregs both in vitro and in vivo. By using this approach it may be possible to attenuate unwanted alloresponses (e.g., graft rejection) or to treat autoimmune diseases.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: T-cell and B-cell Immunology · Immunotherapy and Immune Responses · Immune Cell Function and Interaction
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (59)
Show source-provided references
1. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question10.4049/jimmunol.166.2.973 ↗
2. Immunobiology of rejection and adaptation10.1016/j.transproceed.2007.01.047 ↗
3. Developmental regulation of dendritic cell function10.1016/S0952-7915(99)80049-1 ↗
4. Tolerogenic response: allorecognition pathways10.1016/j.trim.2006.09.034 ↗
5. The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection10.1182/blood.V87.4.1232.bloodjournal8741232 ↗
6. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs10.1053/j.gastro.2010.10.059 ↗
7. Multiple pathways to allograft rejection10.1097/00007890-200205150-00001 ↗
8. Effector mechanisms in transplant rejection10.1046/j.1600-065X.2003.00090.x ↗
9. Alloreactive CD8 T-cell primed/memory responses and accelerated graft rejection in B-cell-deficient sensitized mice10.1097/TP.0b013e31821578da ↗
10. The therapeutic potential of regulatory T cells for the treatment of autoimmune disease10.1517/14728222.2015.1037282 ↗
11. FOXP3+ regulatory T cells: from suppression of rejection to induction of renal allograft tolerance10.1016/j.trim.2011.08.009 ↗
12. CD45 ligation expands Tregs by promoting interactions with DCs10.1172/JCI74087 ↗
13. CD3 antibody and IL-2 complex combination therapy inhibits atherosclerosis by augmenting a regulatory immune response10.1161/JAHA.113.000719 ↗
14. Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model10.1097/TP.0b013e3181ff8772 ↗
15. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells10.1038/nm.2154 ↗
16. Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells10.1097/01.tp.0000250731.44913.ee ↗
17. Absolute of CD4(+)CD25(+)FOXP3(+) regulatory T-cell count rather than its ratio in peripheral blood is related to long-term survival of renal allografts10.1016/j.transproceed.2011.12.014 ↗
18. Do CD4+ Foxp3+ Treg cells correlate with transplant outcomes: a systematic review on recipients of solid organ transplantation10.1016/j.cellimm.2011.05.006 ↗
19. Regulatory T cells in transplantation10.1016/j.transproceed.2011.06.050 ↗
20. Chemical camouflage of antigenic determinants: stealth erythrocytes10.1073/pnas.94.14.7566 ↗
21. Stealth cells: prevention of major histocompatibility complex class II-mediated T-cell activation by cell surface modification10.1182/blood.V94.6.2135 ↗
22. Current and future applications of immunological attenuation via pegylation of cells and tissue10.2165/00063030-200115120-00005 ↗
23. Biophysical consequences of linker chemistry and polymer size on stealth erythrocytes: size does matter10.1016/S0005-2736(02)00339-5 ↗
24. Immunocamouflage: prevention of transfusion-induced graft-versus-host disease via polymer grafting of donor cells10.1002/jbm.a.10146 ↗
25. Comparative analysis of polymer and linker chemistries on the efficacy of immunocamouflage of murine leukocytes10.1080/10731190600683845 ↗
26. Immune complex binding by immunocamouflaged [poly(ethylene glycol)-grafted] erythrocytes10.1002/ajh.20956 ↗
27. Immunocamouflage: the biophysical basis of immunoprotection by grafted methoxypoly(ethylene glycol) [mPeg]10.1016/j.actbio.2010.01.031 ↗
28. Induction of immunotolerance via mPEG grafting to allogeneic leukocytes10.1016/j.biomaterials.2011.08.061 ↗
29. The potential utility of methoxypoly(ethylene Glycol)-mediated prevention of rhesus blood group antigen RhD recognition in transfusion medicine10.1016/j.biomaterials.2011.12.041 ↗
30. Immunocamouflage of latex surfaces by grafted methoxypoly(ethylene glycol) (mPEG): proteomic analysis of plasma protein adsorption10.1007/s11427-012-4290-2 ↗
31. Comparative efficacy of blood cell immunocamouflage by membrane grafting of methoxypoly(ethylene glycol) and polyethyloxazoline10.1016/j.biomaterials.2013.09.016 ↗
32. Effects of methoxypoly (Ethylene glycol) mediated immunocamouflage on leukocyte surface marker detection, cell conjugation, activation and alloproliferation10.1016/j.biomaterials.2015.09.047 ↗
33. Immunogenicity of murine mPEG-red blood cells and the risk of anti-PEG antibodies in human blood donors10.1016/j.exphem.2016.11.001 ↗
34. Inhibition of autoimmune diabetes in NOD mice by miRNA therapy10.1371/journal.pone.0145179 ↗
35. Allorecognition10.1034/j.1600-6143.2001.10201.x ↗
36. Metabolic reprogramming towards aerobic glycolysis correlates with greater proliferative ability and resistance to metabolic inhibition in CD8 versus CD4 T cells10.1371/journal.pone.0104104 ↗
37. CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity10.4049/jimmunol.1200886 ↗
38. Foxp3+ regulatory T cells maintain immune homeostasis in the skin10.1084/jem.20072594 ↗
39. Immunosuppressive therapy in transplantation10.1016/j.cnur.2015.10.008 ↗
40. Pharmacologic immunosuppression10.2741/1249 ↗
41. Immunosuppression: what’s standard and what’s new10.1055/s-0033-1348465 ↗
42. Thymic commitment of regulatory T cells is a pathway of TCR-dependent selection that isolates repertoires undergoing positive or negative selection
43. Nature and nurture: T-cell receptor-dependent and T-cell receptor-independent differentiation cues in the selection of the memory T-cell pool10.1111/j.1365-2567.2010.03338.x ↗
44. Regulatory T cells: mechanisms of differentiation and function10.1146/annurev.immunol.25.022106.141623 ↗
45. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR10.1073/pnas.0800928105 ↗
46. Dominant role of antigen dose in CD4+Foxp3+ regulatory T cell induction and expansion10.4049/jimmunol.0901459 ↗
47. CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects10.1111/j.1600-6143.2007.01829.x ↗
48. Structure of the human class I histocompatibility antigen, HLA-A210.1038/329506a0 ↗
49. Structural features of the αβTCR mechanotransduction apparatus that promote pMHC discrimination
50. CD4: Structure and interactions of an immunoglobulin superfamily adhesion molecule10.1021/ar00032a009 ↗
51. A structural view of CD4 and CD810.1096/fasebj.9.1.7821755 ↗
52. Human gammadelta T cells express a higher TCR/CD3 complex density than alphabeta T cells10.1006/clim.2000.4978 ↗
53. Quantitative analysis of surface marker densities after exposure of T-cells to concanavalin A (Con A): a sensitive early index of cellular activation10.1016/0008-8749(91)90123-S ↗
54. Quantifying the cluster of differentiation 4 receptor density on human T lymphocytes using multiple reaction monitoring mass spectrometry10.1021/ac3031306 ↗
55. Crystal structure of MHC class II I-Ab in complex with a human CLIP peptide: prediction of an I-Ab peptide-binding motif10.1016/S0022-2836(02)01437-7 ↗
56. Polymer therapeutics: concepts and applications10.1002/anie.200502113 ↗
57. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins10.1159/000233309 ↗
58. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors10.1159/000233512 ↗
59. CD8+ T cells in autoimmunity10.1016/j.coi.2005.09.014 ↗